EP2403476A1 - Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail - Google Patents

Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail

Info

Publication number
EP2403476A1
EP2403476A1 EP10707032A EP10707032A EP2403476A1 EP 2403476 A1 EP2403476 A1 EP 2403476A1 EP 10707032 A EP10707032 A EP 10707032A EP 10707032 A EP10707032 A EP 10707032A EP 2403476 A1 EP2403476 A1 EP 2403476A1
Authority
EP
European Patent Office
Prior art keywords
water
pharmaceutical composition
antifungal agent
terbinafine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10707032A
Other languages
German (de)
French (fr)
Inventor
Claire Mallard
Nathalie Willcox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of EP2403476A1 publication Critical patent/EP2403476A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Definitions

  • the present invention relates to the development of a ternary solvent system comprising water that allows substantial amounts of antifungal agents from the class of the allylamines or from the class of the morpholines to be dissolved.
  • This invention allows compositions to be prepared that are specifically adapted to application to the nail, the latter possibly being optionally perforated or pretreated chemically or physically.
  • Pharmaceutical or dermatological compositions of this kind are useful especially for the treatment, in humans and animals, of onychomycoses, especially those due to dermatophytes or to Candida.
  • Antifungal agents from the class of the allylamines, especially terbinafine or naftifine, and those from the class of the morpholines, especially amorolfine, are promising compounds in antifungal control. Their presumed or demonstrated mode of action involves inhibition at the level of ergosterol, a specific constituent of the wall of fungal cells, especially via the inhibition of squalene epoxidase ("Terbinafine: Mode of action and properties of the squalene epoxidase inhibition" British Journal of Dermatology, Volume 126 Issue s39, pages 2-69 (February 1992); "Preclinical data and mode of action of amorolfine", Dermatology, 1992, vol. 184, SUPl (10 ref . ) , pp. 3-7) . Traditionally, antifungals have been administered either topically or orally.
  • terbinafine administered at a level of 250 mg/day for 6 months has proved to be effective and of low toxicity in the treatment of onychomycoses due to Trichophyton rubrum.
  • treatment of this kind raises a problem of duration and of cost, and sometimes has side-effects affecting the digestive sphere, taste disorders or else transitory skin eruptions (GUPTA A, LYNDE C, LAUZON G et al . Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol, 1998, 138: 529-532) .
  • transungual administration represents an alternative solution to oral administration for the treatment of onychomycoses.
  • the problem which arises in the case of administration to the nail is to ensure the penetration and spreading of the antifungal agents in the nail, allowing therapeutically effective concentrations to be attained in the nail and under the nail, in other words in the nail bed.
  • the nail as such is composed essentially of keratin, a fibrous protein which is indeed insoluble yet which exhibits an affinity for water.
  • the nail is considered to be hydrophilic in nature, which is to say that it behaves as a hydrogel. Consequently, and for transungual application, it would appear mandatory to formulate the antifungal agent in water.
  • Water however, has difficulties in its compatibility with the aforementioned antifungal agents of interest, especially terbinafine, which per se exhibit little spreading ability into the nail, and, moreover, are virtually insoluble in water.
  • the solution used has been that of an aqueous-alcoholic mixture with addition of polymers.
  • document EP 0 503 988 proposed admixing the aqueous-alcoholic medium with hydrophilic penetrants, which were hitherto known and used for promoting the transcutaneous penetration of active agents through the horny layer of the skin; this horny layer is lipophilic in nature and behaves as a water barrier .
  • the present invention lies in the demonstration of a ternary solvent system which comprises water and which combines a capacity for substantial amounts of antifungal agents of interest to be dissolved, the possibility of a large amount of water, and a capacity for effective spreading and effective penetration into and through the keratinized ungual tablet of the nail.
  • large amount of water is meant a total amount of water in the composition of more than 30% by weight, relative to the total weight of the composition.
  • the present invention provides a dermatological composition intended for the treatment of onychomycoses, which takes the form of a solution and comprises: first, an effective amount of at least one antifungal agent; second, a solvent medium for said antifungal agent (or agents) that is composed of a mixture of water, at least one branched or straight chain C2-C8 alkanol, and at least one glycol that has free hydroxyl functions.
  • a composition of this kind is characterized in that the total water represents more than 30% by weight, relative to the total weight of the composition
  • an "effective amount" of at least one antifungal agent is a substantial amount of said agent in the composition. It is obvious that the problem of solubility in the solvent medium, more particularly in water, arises for substantial amounts of this kind.
  • the substantial amount of antifungal agent represents more than 5%, or even at least 8%, or, indeed, even at least 10% (w/w) of the total composition. Hence it is possible to envisage up to 15% or even 20% of this agent in the composition .
  • the antifungal agents of interest that are more particularly a target of the present invention are those from the class of the allylamines and from the class of the morpholines, the class of the allylamines being preferred.
  • terbinafine and its acid salts preference will be given to terbinafine hydrochloride and naftifine hydrochloride, the respective formulae of which are as follows:
  • Naftifine hydrochloride Among the molecules from this class, preference is given to terbinafine.
  • the antifungal agent may belong to the class of the morpholines, especially amorphine and its acid salts, for which similar problems of solubility in water arise.
  • the invention is based on the demonstration of a ternary solvent system comprising water and exhibiting a synergy in the dissolution of the antifungal agents of interest.
  • This system comprises: water, which is known to be a very poor solvent of antifungal agents from the class of the allylamines or from that of the morpholines; - a short chain alcohol, and more specifically, at least one branched or straight chain C2-C8 alkanol, these alcohols being known to be solvents for antifungal agents from the class of the allylamines or from that of the morpholines; at least one glycol.
  • a very poor solvent is a solvent which allows dissolution of not more than 1% (w/w) of the antifungal agent from the class of the allylamines or from that of the morpholines.
  • the total water represents more than 30% by weight, relative to the total weight of the composition (w/w) , advantageously more than 33%, or even more than 35% or, indeed, even more than 40%. Consequently, the total water advantageously represents more than a third of the ternary solvent mixture.
  • total water is meant the amount of water introduced as such into the composition, with the addition of the amount of water originating from the various solvents and/or excipients in the composition, where they contain water.
  • the total water represents advantageously less than 60%, or even less than 50%, of the total composition.
  • the second entity in this ternary system is a short chain alcohol, and more specifically at least one branched or straight chain C2-C8 alkanol, preferably ethanol, isopropanol and n-butanol. Ethanol is particularly preferred. A mixture of different alcohols may also be contemplated.
  • this ternary solvent system comprises at least one glycol.
  • a glycol here is a compound which has at least two hydroxyl functions.
  • the invention relates more particularly to glycols whose two hydroxyl functions are free, which is to say that they are not engaged in an ether or ester linkage.
  • Such glycols include, for example, propylene glycol, butylene glycol, hexylene glycol, ethylene glycol and polyethylene glycols. Propylene glycol is preferred.
  • a mixture of different glycols may also be contemplated.
  • the ternary solvent system represents at least 60%, or even 70%, 80%, or, indeed, even 90% (w/w) of the total
  • the proportion of alcohol is greater than or equal to that of glycol. Even more advantageously, the total proportion of water is greater than that of glycol.
  • a pharmaceutical or dermatological composition according to the invention takes the form of a solution. It may equally be formulated as a lotion, spray, emulsion, foam or gel, which advantageously is fluid.
  • composition according to the invention may also include at least one additive selected from the group consisting of: preservatives, such as phenylethyl alcohol, benzyl alcohol and phenoxyethanol, parabens and derivatives; antioxidants, such as butylated hydroxyanisole (BHA) , butylated hydroxytoluene (BHT) , palmityl ascorbate, alpha-tocopherol and/or its esters; dyes, fillers or pigments, such as the titanium micas commonly used in the cosmetics field for producing nail varnish; - polymers capable of preventing the flow of the composition before penetration, such as, for example, alkylcellulose derivatives, especially methylcelluloses, ethylcelluloses and hydroxy- alkylcelluloses, such as those sold under the name "KLUCEL”; chelating agents such as disodium edetate (EDTA) ; emollients such as cyclomethicone; antiseptics, especially acetic acid or chlorhex
  • composition according to the invention is particularly adapted for the treatment of onychomycoses transungually . Hence it is intended for application to the surface of the nail.
  • - antifungal agent terbinafine hydrochloride (terbinafine HCl)
  • water purified water
  • alcohol ethanol
  • glycol propylene glycol
  • Terbinafine HCl is weighed out accurately into a 20 ml flask and then the solvents are added. The flask is subsequently placed, with magnetic stirring, in a chamber thermostated at 20 0 C, for 16 h. If some of the active ingredient has not dissolved, a further addition of solvent is made. The flask is then placed again, with magnetic stirring, in the thermostated chamber, for 16 h, until dissolution is complete. If this is not so, the preceding step is repeated.
  • the standard range is produced by varying the injection volume of solution A, at an equivalent concentration of 4 ⁇ g/ml to 120 ⁇ g/ml .
  • the visual solubility of the terbinafine HCl is 19.7% w/w, confirmed at 18.09% w/w by HPLC assay;
  • the visual solubility of the terbinafine HCl is 23.3% w/w, confirmed at 20.4% w/w by HPLC assay.
  • the visual solubility of the terbinafine HCl is 0.6% w/w. In the case of a binary water/ethanol mixture (50/50), the visual solubility of the terbinafine HCl is 16.7% w/w, in other words below that obtained with ethanol alone.
  • the amount of water was then increased to 30% in the presence of equivalent amounts of 35% of propylene glycol and 35% of ethanol.
  • the visual solubility of the terbinafine HCl is then 18.5% w/w, i.e. well above 10%, a concentration determined as being optimum in terms of the biological activity of the active principle .
  • the water reduces the solubility of the terbinafine HCl. Therefore, only the combination of a ternary water/propylene glycol/ethanol mixture makes it possible to increase the solubility of terbinafine HCl. It has thus been shown that the solubility of terbinafine HCl is greater than 10% in a ternary water/propylene glycol/ethanol mixture containing at least 30% of water (Graph 1) . The solubility of terbinafine remains greater than 10% with 40% of water, with the proviso that the amount of ethanol is at least greater than or equal to that of the propylene glycol.
  • compositions based on the ternary solvent system allowed various formulations to be produced, containing substantial amounts of terbinafine HCl, with no solubility problem.
  • the examples below are given by way of illustration, and are not at all limitative. For each example, the formula is expressed as a function of the percent of each ingredient used as sold (1st column) .
  • the formula is also expressed by taking account of the water present in each ingredient. In this case, the % corresponding to the ingredients are considered to add up to 100% (2nd column) .
  • the formulations are prepared by following procedure:
  • Step 1 Dissolve the hydroxytoluene in ethanol.
  • Step 2 When the Butylhydroxytoluene is fully dissolved, add successively:
  • Step 3 add terbinafine HCL mixture obtained in step 2.
  • the physical and chemical stabilities were measured for 3 months at room temperature and at 40 0 C.
  • the physical and chemical stabilities were measured for 3 months at room temperature and at 40 0 C.
  • Example 3 Hydroxyethy1cellulose 0.50% 0.50%
  • This ternary propylene glycol/ethanol/water mixture therefore exhibits a synergistic effect in the dissolution of terbinafine HCl in the proportions used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a pharmaceutical composition which comprises: -an antifungal agent from the class of the allylamines or the morpholines, at a concentration of at least 5 %; -a ternary solvent system comprising water; at least one branched or straight chain C2-C8 alkanol; at least one glycol; the total amount of water representing more than 30 % (w/w) of the composition. This composition is intended for application to the nail for the treatment of onychomycoses.

Description

METHOD OF DISSOLVING ANTIFUNGAL AGENT, AND COMPOSITIONS
WITH A HIGH CONCENTRATION OF ANTIFUNGAL AGENT, SUITABLE
FOR APPLICATION TO THE NAIL
TECHNICAL BACKGROUND
The present invention relates to the development of a ternary solvent system comprising water that allows substantial amounts of antifungal agents from the class of the allylamines or from the class of the morpholines to be dissolved. This invention allows compositions to be prepared that are specifically adapted to application to the nail, the latter possibly being optionally perforated or pretreated chemically or physically. Pharmaceutical or dermatological compositions of this kind are useful especially for the treatment, in humans and animals, of onychomycoses, especially those due to dermatophytes or to Candida.
PRIOR ART
Antifungal agents from the class of the allylamines, especially terbinafine or naftifine, and those from the class of the morpholines, especially amorolfine, are promising compounds in antifungal control. Their presumed or demonstrated mode of action involves inhibition at the level of ergosterol, a specific constituent of the wall of fungal cells, especially via the inhibition of squalene epoxidase ("Terbinafine: Mode of action and properties of the squalene epoxidase inhibition" British Journal of Dermatology, Volume 126 Issue s39, pages 2-69 (February 1992); "Preclinical data and mode of action of amorolfine", Dermatology, 1992, vol. 184, SUPl (10 ref . ) , pp. 3-7) . Traditionally, antifungals have been administered either topically or orally.
By the oral route, terbinafine administered at a level of 250 mg/day for 6 months has proved to be effective and of low toxicity in the treatment of onychomycoses due to Trichophyton rubrum. However, treatment of this kind raises a problem of duration and of cost, and sometimes has side-effects affecting the digestive sphere, taste disorders or else transitory skin eruptions (GUPTA A, LYNDE C, LAUZON G et al . Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol, 1998, 138: 529-532) .
By the topical route, transungual administration represents an alternative solution to oral administration for the treatment of onychomycoses. However, the problem which arises in the case of administration to the nail is to ensure the penetration and spreading of the antifungal agents in the nail, allowing therapeutically effective concentrations to be attained in the nail and under the nail, in other words in the nail bed.
The nail as such is composed essentially of keratin, a fibrous protein which is indeed insoluble yet which exhibits an affinity for water. Thus the nail is considered to be hydrophilic in nature, which is to say that it behaves as a hydrogel. Consequently, and for transungual application, it would appear mandatory to formulate the antifungal agent in water. Water, however, has difficulties in its compatibility with the aforementioned antifungal agents of interest, especially terbinafine, which per se exhibit little spreading ability into the nail, and, moreover, are virtually insoluble in water. Among all of the technical solutions proposed for transungual formulations of antifungal agents in the prior art, the solution used has been that of an aqueous-alcoholic mixture with addition of polymers.
Alternatively, document EP 0 503 988 proposed admixing the aqueous-alcoholic medium with hydrophilic penetrants, which were hitherto known and used for promoting the transcutaneous penetration of active agents through the horny layer of the skin; this horny layer is lipophilic in nature and behaves as a water barrier .
However, even in the presence of such hydrophilic penetrants, the proportion of water in the compositions described in document EP 0 503 988 is never greater than 30% of the total weight of the composition.
There is therefore a need to find new formulations for antifungal agents that allow improved spreading through the nail of an effective amount of active principle .
SUMMARY OF THE INVENTION
The present invention lies in the demonstration of a ternary solvent system which comprises water and which combines a capacity for substantial amounts of antifungal agents of interest to be dissolved, the possibility of a large amount of water, and a capacity for effective spreading and effective penetration into and through the keratinized ungual tablet of the nail.
By "large amount of water" is meant a total amount of water in the composition of more than 30% by weight, relative to the total weight of the composition.
More specifically, the present invention provides a dermatological composition intended for the treatment of onychomycoses, which takes the form of a solution and comprises: first, an effective amount of at least one antifungal agent; second, a solvent medium for said antifungal agent (or agents) that is composed of a mixture of water, at least one branched or straight chain C2-C8 alkanol, and at least one glycol that has free hydroxyl functions.
A composition of this kind is characterized in that the total water represents more than 30% by weight, relative to the total weight of the composition
(w/w) , advantageously more than 33%, or even more than
35%, or, indeed, even more than 40%.
In the context of the invention, an "effective amount" of at least one antifungal agent is a substantial amount of said agent in the composition. It is obvious that the problem of solubility in the solvent medium, more particularly in water, arises for substantial amounts of this kind.
In practice, the substantial amount of antifungal agent, as will be defined below, represents more than 5%, or even at least 8%, or, indeed, even at least 10% (w/w) of the total composition. Hence it is possible to envisage up to 15% or even 20% of this agent in the composition .
It is of course possible to contemplate a mixture of antifungal agents, possibly from different classes.
As already stated, the antifungal agents of interest that are more particularly a target of the present invention are those from the class of the allylamines and from the class of the morpholines, the class of the allylamines being preferred.
Within the class of the allylamines, mention may be made, in particular, of terbinafine and its acid salts, and naftifine and its acid salts. Among the acid salts, preference will be given to terbinafine hydrochloride and naftifine hydrochloride, the respective formulae of which are as follows:
Terbinafine hydrochloride
Naftifine hydrochloride Among the molecules from this class, preference is given to terbinafine.
Alternatively, the antifungal agent may belong to the class of the morpholines, especially amorphine and its acid salts, for which similar problems of solubility in water arise.
As indicated above, the invention is based on the demonstration of a ternary solvent system comprising water and exhibiting a synergy in the dissolution of the antifungal agents of interest. This system comprises: water, which is known to be a very poor solvent of antifungal agents from the class of the allylamines or from that of the morpholines; - a short chain alcohol, and more specifically, at least one branched or straight chain C2-C8 alkanol, these alcohols being known to be solvents for antifungal agents from the class of the allylamines or from that of the morpholines; at least one glycol.
A very poor solvent is a solvent which allows dissolution of not more than 1% (w/w) of the antifungal agent from the class of the allylamines or from that of the morpholines.
Hence, remarkably, the inventors have demonstrated that this combination of three solvents comprising water exhibits a synergy in the dissolution of the antifungal agents of interest, thereby allowing the amount of water in the mixture to be increased while at the same time allowing the dissolution of substantial amounts of antifungal agents.
As already stated, and remarkably, the total water represents more than 30% by weight, relative to the total weight of the composition (w/w) , advantageously more than 33%, or even more than 35% or, indeed, even more than 40%. Consequently, the total water advantageously represents more than a third of the ternary solvent mixture. By total water is meant the amount of water introduced as such into the composition, with the addition of the amount of water originating from the various solvents and/or excipients in the composition, where they contain water.
On the other hand, the total water represents advantageously less than 60%, or even less than 50%, of the total composition.
The second entity in this ternary system is a short chain alcohol, and more specifically at least one branched or straight chain C2-C8 alkanol, preferably ethanol, isopropanol and n-butanol. Ethanol is particularly preferred. A mixture of different alcohols may also be contemplated. Lastly, this ternary solvent system comprises at least one glycol. A glycol here is a compound which has at least two hydroxyl functions. The invention relates more particularly to glycols whose two hydroxyl functions are free, which is to say that they are not engaged in an ether or ester linkage. Such glycols include, for example, propylene glycol, butylene glycol, hexylene glycol, ethylene glycol and polyethylene glycols. Propylene glycol is preferred. A mixture of different glycols may also be contemplated. Advantageously, the ternary solvent system represents at least 60%, or even 70%, 80%, or, indeed, even 90% (w/w) of the total composition.
Moreover, and advantageously, the proportion of alcohol is greater than or equal to that of glycol. Even more advantageously, the total proportion of water is greater than that of glycol.
Generally speaking, a pharmaceutical or dermatological composition according to the invention takes the form of a solution. It may equally be formulated as a lotion, spray, emulsion, foam or gel, which advantageously is fluid.
The composition according to the invention may also include at least one additive selected from the group consisting of: preservatives, such as phenylethyl alcohol, benzyl alcohol and phenoxyethanol, parabens and derivatives; antioxidants, such as butylated hydroxyanisole (BHA) , butylated hydroxytoluene (BHT) , palmityl ascorbate, alpha-tocopherol and/or its esters; dyes, fillers or pigments, such as the titanium micas commonly used in the cosmetics field for producing nail varnish; - polymers capable of preventing the flow of the composition before penetration, such as, for example, alkylcellulose derivatives, especially methylcelluloses, ethylcelluloses and hydroxy- alkylcelluloses, such as those sold under the name "KLUCEL"; chelating agents such as disodium edetate (EDTA) ; emollients such as cyclomethicone; antiseptics, especially acetic acid or chlorhexidine .
The amounts of each of these additives are readily determined by a person skilled in the art.
As already stated, a composition according to the invention is particularly adapted for the treatment of onychomycoses transungually . Hence it is intended for application to the surface of the nail.
WORKING EXAMPLES
The invention and its attendant advantages will emerge more clearly from the working examples which follow. In no case, however, are these examples limitative .
In these examples, the following compounds were tested: - antifungal agent = terbinafine hydrochloride (terbinafine HCl) ; water = purified water; alcohol = ethanol; glycol = propylene glycol. 1/ Demonstration of synergy of the ternary solvent system for the dissolution of the antifungal agent:
Different solubility tests on terbinafine HCl were carried out in different solvent systems. The solubility was both estimated visually by Method 1 below, then quantified by HPLC assay by Method 2 below.
Method 1: Dissolution of the terbinafine HCl
Terbinafine HCl is weighed out accurately into a 20 ml flask and then the solvents are added. The flask is subsequently placed, with magnetic stirring, in a chamber thermostated at 200C, for 16 h. If some of the active ingredient has not dissolved, a further addition of solvent is made. The flask is then placed again, with magnetic stirring, in the thermostated chamber, for 16 h, until dissolution is complete. If this is not so, the preceding step is repeated.
Method 2 : Quantification of the terbinafine by HPLC
PREPARATION OF SOLUTIONS:
Diluent:
Stock solutions
Solution A (300 μg/ml)
Weigh out precisely approximately 15 mg of terbinafine HCl into a 50 ml volumetric flask. Dissolve in the diluent and make up to the volume with the same solvent. Prepare the solution in duplicate (Al, A2)
Daughter solution (60 μg/ml) Dilute solution A to 1/5 in the diluent. Dilution A1=>STD1, dilution A2→STD2 Standard range
The standard range is produced by varying the injection volume of solution A, at an equivalent concentration of 4 μg/ml to 120 μg/ml .
Sample solutions
2 tests per sample are prepared, of concentrations from 40 μg/ml to 100 μg/ml.
OPERATING CONDITIONS
Eluent phase
Parameters of the chromatography system
Column : Sun Fire C18 4.6 X 100 mm 3.5 μm, fitted with a precolumn.
Column temperature: 300C Flow rate: 1.5 ml/min Injected volume: 30 μl for the sample solutions Analysis time: 10 min
Detection at: 285 nm
Gradient :
Chromatography system conformity test
Inject the control solution STD 6 times, and, on the peak of the assayed active ingredient, measure the following parameters:
Inject a blank sample (diluent) and check that no peak of the blank sample interferes with the terbinafine HCl .
Inject solutions STDl and STD2 and check that the % deviation between the 2 controls is < 2%.
A/ Binary solvent system:
A-I/ Ethanol/propylene glycol
- In ethanol, the visual solubility of the terbinafine HCl is 19.7% w/w, confirmed at 18.09% w/w by HPLC assay;
- In propylene glycol, the visual solubility of the terbinafine HCl is 8.9% w/w, confirmed at 10.3% w/w by HPLC assay;
- In a 50/50 ethanol/propylene glycol mixture, the visual solubility of the terbinafine HCl is 23.3% w/w, confirmed at 20.4% w/w by HPLC assay.
In conclusion, although propylene glycol is not as good a solvent of the terbinafine HCl as is ethanol, the solubility obtained in the binary mixture is slightly greater than that obtained in ethanol. By additive effect, the expected solubility of the terbinafine HCl would have been of the order of 14%. The fact that a solubility of the order of 20% is measured demonstrates the existence of a synergy in the dissolution of terbinafine HCl between propylene glycol and ethanol.
A-2/ Water/ethanol
In water, the visual solubility of the terbinafine HCl is 0.6% w/w. In the case of a binary water/ethanol mixture (50/50), the visual solubility of the terbinafine HCl is 16.7% w/w, in other words below that obtained with ethanol alone.
A-3/ Water/propylene glycol
In the case of a binary water/propylene glycol mixture (50/50), the visual solubility of the terbinafine HCl drops to 2.2% w/w, i.e. slightly less than that obtained with propylene glycol alone. In conclusion, in the binary water/propylene glycol and water/ethanol mixtures, the water lowers the solubility of the terbinafine HCl by comparison, respectively, with the solubilities obtained in propylene glycol and in ethanol.
B/ Ternary solvent system:
When 15% of water is introduced into a mixture composed either of 70% of propylene glycol and 15% of ethanol, or of 70% of ethanol and 15% of propylene glycol, the visual solubility of the terbinafine HCl goes up, surprisingly, and reaches 25.0% w/w and 25.2% w/w, respectively.
In conclusion, and in contrast to any expectation, the introduction of water (qs 100%) into a binary propylene glycol/ethanol mixture (70/15 or 15/70) increases, surprisingly, the solubility of the terbinafine HCl, although water is a poor solvent per se for terbinafine HCl. There is therefore a synergy, in terms of dissolution, of terbinafine HCl in a ternary propylene glycol/ethanol/water mixture.
In order to come close to optimal conditions for transungual application, namely a large amount of water in the pharmaceutical composition and an amount of terbinafine HCl of at least 10%, the amount of water was then increased to 30% in the presence of equivalent amounts of 35% of propylene glycol and 35% of ethanol.
Under these conditions, the visual solubility of the terbinafine HCl is then 18.5% w/w, i.e. well above 10%, a concentration determined as being optimum in terms of the biological activity of the active principle .
When the amount of water is increased to 33% in the presence of equivalent amounts of propylene glycol (33%) and ethanol (33%) , the visual solubility of terbinafine HCl is 15.5% w/w, i.e. still above 10%.
In conclusion, it appears that water, which is desirable for providing moisture to the nail in the intended application, and hence promoting improved spreading of the antifungal agent within the nail matrix, makes it possible to increase the solubility of terbinafine HCl, in spite of its poor solvency for this antifungal agent. This increase in solubility is dependent on the combination propylene glycol and ethanol.
As already seen above, in a binary water/propylene glycol or water/ethanol mixture, the water reduces the solubility of the terbinafine HCl. Therefore, only the combination of a ternary water/propylene glycol/ethanol mixture makes it possible to increase the solubility of terbinafine HCl. It has thus been shown that the solubility of terbinafine HCl is greater than 10% in a ternary water/propylene glycol/ethanol mixture containing at least 30% of water (Graph 1) . The solubility of terbinafine remains greater than 10% with 40% of water, with the proviso that the amount of ethanol is at least greater than or equal to that of the propylene glycol.
It has thus been possible to define the proportions of a ternary propylene glycol/ethanol/water mixture that allow at least 10% of terbinafine HCl to be dissolved, and in which the total amount of water is at least 30%, an amount of water necessary for obtaining improved spreading of the terbinafine within the nail matrix.
2/ Compositions based on the ternary solvent system: The ternary solvent system as defined allowed various formulations to be produced, containing substantial amounts of terbinafine HCl, with no solubility problem. The examples below are given by way of illustration, and are not at all limitative. For each example, the formula is expressed as a function of the percent of each ingredient used as sold (1st column) .
The formula is also expressed by taking account of the water present in each ingredient. In this case, the % corresponding to the ingredients are considered to add up to 100% (2nd column) .
The formulations are prepared by following procedure:
Step 1: Dissolve the hydroxytoluene in ethanol.
Step 2: When the Butylhydroxytoluene is fully dissolved, add successively:
PROPYLENE GLYCOL
PURIFIED WATER EDTA
Stirring until complete solubilization of EDTA.
Step 3: add terbinafine HCL mixture obtained in step 2.
Let stirring until complete solubilization. Example 1
The physical and chemical stabilities were measured for 3 months at room temperature and at 400C.
Physical stability:
Specifications at TO
Macroscopic appearance: clear, colourless solution
Microscopic appearance: absence of crystals of terbinafine HCl
Chemical stability:
Example 2 :
The physical and chemical stabilities were measured for 3 months at room temperature and at 400C.
Physical stability:
Specifications at TO Macroscopic appearance: clear, colourless, slightly viscous solution Microscopic appearance: absence of crystals of terbinafine HCl Chemical stability:
Example 3 : Hydroxyethy1cellulose 0.50% 0.50%
Butylated 0 .04% 0 .04% hydroxytoluene
EDTA 0 .01% 0 .01%
Cyclomethicone 5% 5%
Example 4 :
Ingredients (w/w) Formula Formula
(% per (% taking account ingredient) of the water present in each ingredient)
Terbinafine HCl 10! 10!
Purified water 38.75% /
Total water (purified / 38.75 + (31.50 X water + water present 0.05) = 40.32% in the ingredients)
Propylene glycol 18.90% 18.90%
Ethanol 100- / 31.50 - (31.5 x 0.05) = 29.93%
Ethanol 95-96^ 31.50; /
Hydroxyethy1cellulose 0.30! 0.30!
Butylated 0.04! 0.04! hydroxytoluene
EDTA 0.01! O.OΓ
Acetic acid 0.50! 0.50!
Example 5 :
By using the ternary propylene glycol/ethanol/water mixture in certain proportions, we have demonstrated that it is possible to obtain a terbinafine HCl solubility which is much greater than that obtained in each solvent taken separately.
This ternary propylene glycol/ethanol/water mixture therefore exhibits a synergistic effect in the dissolution of terbinafine HCl in the proportions used.
On the basis of this ternary propylene glycol/ethanol/- water mixture, it was possible to produce stable compositions containing a minimum of 30% of total water, while permitting solubilization of a terbinafine HCl content of 10% w/w.

Claims

1. Pharmaceutical composition comprising: an antifungal agent from the class of the allylamines or the morpholines, at a concentration of at least 5%; a ternary solvent system comprising
• water;
• at least one branched or straight chain C2-C8 alkanol;
• at least one glycol; the total amount of water representing more than 30% of the composition.
2. Pharmaceutical composition according to Claim 1, characterized in that the antifungal agent is terbinafine or one of its acid salts.
3. Pharmaceutical composition according to Claim 2, characterized in that the acid salt of terbinafine is terbinafine hydrochloride.
4. Pharmaceutical composition according to any of the preceding claims, characterized in that the concentration of antifungal agent is greater than or equal to 8%, preferably greater than or equal to 10%.
5. Pharmaceutical composition according to any of the preceding claims, characterized in that the alkanol is ethanol.
6. Pharmaceutical composition according to any of the preceding claims, characterized in that the glycol is propylene glycol.
7. Pharmaceutical composition according to any of the preceding claims, characterized in that it takes the form of a lotion, spray, emulsion, foam or gel.
8. Pharmaceutical composition according to any of the preceding claims, characterized in that it further comprises at least one compound selected from the following list: chelating agent, antioxidant, polymer, antiseptic agent, emollient.
9. Use of a pharmaceutical composition according to any of Claims 1 to 8 for preparing a medicament intended for application to the nail for the treatment of onychomycos
EP10707032A 2009-03-06 2010-03-05 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail Withdrawn EP2403476A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20251609P 2009-03-06 2009-03-06
FR0951416A FR2942716B1 (en) 2009-03-06 2009-03-06 METHOD FOR SOLUBILIZING ANTIFUNGAL AGENT AND COMPOSITIONS HAVING HIGH CONCENTRATION OF ANTIFUNGAL AGENT APPLICABLE ON THE NATIVE
PCT/EP2010/052817 WO2010100252A1 (en) 2009-03-06 2010-03-05 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail

Publications (1)

Publication Number Publication Date
EP2403476A1 true EP2403476A1 (en) 2012-01-11

Family

ID=41056884

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10707032A Withdrawn EP2403476A1 (en) 2009-03-06 2010-03-05 Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail

Country Status (11)

Country Link
EP (1) EP2403476A1 (en)
JP (1) JP2012519669A (en)
KR (1) KR20110121702A (en)
CN (1) CN102341092A (en)
AU (1) AU2010220266A1 (en)
BR (1) BRPI1006666A2 (en)
CA (1) CA2753638A1 (en)
FR (1) FR2942716B1 (en)
MX (1) MX2011009093A (en)
RU (1) RU2011140574A (en)
WO (1) WO2010100252A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
EP2672962B1 (en) * 2011-02-11 2015-03-25 Moberg Pharma AB Novel antifungal composition
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN110433291B (en) 2013-10-03 2023-04-28 博世健康爱尔兰有限公司 Stable ifetroconazol compositions
CA3052643A1 (en) 2013-11-22 2015-05-28 Bausch Health Ireland Limited Anti-infective methods, compositions, and devices
NZ731143A (en) * 2014-10-21 2021-07-30 Hexima Ltd A method of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673537B1 (en) * 1991-03-08 1993-06-11 Oreal USE OF HYDROPHILIC PENETRATION AGENTS IN DERMATOLOGICAL COMPOSITIONS FOR THE TREATMENT OF ONYCHOMYCOSES, AND CORRESPONDING COMPOSITIONS.
HU219480B (en) * 1991-05-23 2001-04-28 Novartis Ag. Process for producing locally applicable pharmaceutical compositions comprising allylamine derivative against fungus infection of nails
US20080261986A1 (en) * 2007-03-30 2008-10-23 Friden Phillip M Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010100252A1 *

Also Published As

Publication number Publication date
MX2011009093A (en) 2011-09-27
KR20110121702A (en) 2011-11-08
AU2010220266A1 (en) 2011-09-08
FR2942716A1 (en) 2010-09-10
CA2753638A1 (en) 2010-09-10
WO2010100252A1 (en) 2010-09-10
FR2942716B1 (en) 2011-04-15
JP2012519669A (en) 2012-08-30
CN102341092A (en) 2012-02-01
RU2011140574A (en) 2013-04-20
BRPI1006666A2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
WO2010100252A1 (en) Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
EP2191826B1 (en) Pharmaceutical composition
EP2191828B1 (en) Antifungal pharmaceutical composition
EP2704703B1 (en) Transdermal compositions of ibuprofen and methods of use thereof
CA3020157C (en) Topical composition comprising tacrolimus
JP2555555B2 (en) Antifungal topical formulation
US20120328543A1 (en) Use of a cationic, advantageously amphoteric, surfactant for the preparation of an antifungal solution that can be applied to the nail
JP5033381B2 (en) Pharmaceutical composition for external use
AU2020236525B2 (en) Stable topical compositions of Fenoldopam
US20120309753A1 (en) Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
EP3666254A2 (en) Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
WO2007086582A1 (en) OIL-IN-WATER TYPE EMULSION LOTION CONTAINING 22-OXA-1α,25-DIHYDROXYVITAMIN D3 AND METHOD OF TREATING SKIN DISEASE BY USING THE SAME
JP4060347B2 (en) Oil-in-water emulsion lotion containing 22-oxa-1α, 25-dihydroxyvitamin D3
JP5460766B2 (en) Pharmaceutical composition for external use
JPH111433A (en) Tolnaftate-containing liquid agent
US20240131008A1 (en) topical formulation of Disease-Modifying Antirheumatic Drug (DMARDs) for treatment of rheumatoid arthritis, melanoma, squamous cell carcinoma, atopic dermatitis and psoriasis
WO2023016583A1 (en) Ruxolitinib composition and use thereof
EP4342449A1 (en) Hydroalcoholic single phase gel compositions for topical delivery of diclofenac
EP4342450A1 (en) Hydroalcoholic topical diclofenac formulations
WO2023172216A1 (en) Hydrocortisone and pramoxine topical formulations having enhanced in-vitro release

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA ME RS

17Q First examination report despatched

Effective date: 20140911

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150122